Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Phase 3 Completed 208 enrolled Progenics Pharmaceuticals, Inc.

NaSingle-groupOpen-labelDiagnostic

Summary

This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Timeline

Start: 2018-11-27
Primary completion: 2019-08-29
Completion: 2019-08-29

Outcome

Met primary endpoint

release “CONDOR found that a PSMA-targeted PET scan with PYLARIFY in men with biochemical recurrent prostate cancer achieved the primary endpoint of correct localization rate (CLR)” lantheus.com ↗

Publications

Agarwal G, Sangwan K. FDA-Approved Radiopharmaceuticals in Oncologic PET Imaging: Current Status and Clinical Impact. Am J Clin Oncol. 2026 Mar 4. doi: 10.1097/COC.0000000000001314. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	18F-DCFPyL	Diagnostic / imaging agent	333 mbq	Intravenous